Clinical trials: Erythema Multiforme
Dialysis Access Malfunction, End Stage Renal Failure on Dialysis
MAgicTouch™ Intervention Leap for Dialysis Access (MATILDA) Trial
For patients with End Stage Renal Failure (ESRF), the surgical creation of an Autogenous Arteriovenous Fistula (AVF) or Autogenous Arteriovenous Graft (AVG) is the recognised standard for providing vascular access.
- Conditions
- Dialysis Access Malfunction, End Stage Renal Failure on Dialysis, End Stage Renal Disease, Fistulas Arteriovenous
- Trial name
- MATILDA (NCT04698512)
- Testing
- AVFistuloplasty with Sirolimus coated balloon
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- Singapore General Hospital
Toxic Epidermal Necrolysis
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis
- Trial name
- TEN (NCT06119490)
- Testing
- Abrocitinib, Tofacitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peng Zhang
Toxic Epidermal Necrolysis, Immunotherapy
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Toxic Epidermal Necrolysis (TEN) are rare diseases that are dermatologic emergencies characterized by widespread epidermal necrosis and sloughing of skin. A hundred patients are affected each year in France.
- Conditions
- Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
- Trial name
- NET-CD38 (NCT07110662)
- Testing
- DARATUMUMAB (DARZALEX®)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Hospices Civils de Lyon
Toxic Epidermal Necrolysis
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.
- Trial name
- NCT00372723
- Testing
- Remicaide (infliximab)
- Sponsor
- Loyola University
Epilepsy, Neuropathy
HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions
Cutaneous adverse drug reactions (cADRs) include mild maculopapular exanthema (MPE) and severe cutaneous reactions such as hypersensitivity syndrome, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).
- Conditions
- Epilepsy, Neuropathy, Psychiatric Illness, Blepharospasm
- Trial name
- NCT03184597
- Testing
- HLA screening before commencing aromatic AEDs
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Urinary Incontinence
Urinary Continence Index for Prediction of Urinary Incontinence in Older Women
This study will analyse existing data to establish a clinically useful index to predict those women who are more likely to become incontinent.
- Trial name
- NCT01479816
- Where
- 2 sites in United States
- Volunteers
- 702 people
- Sponsor
- Ananias Diokno
Neuralgia, Postherpetic
Lamictal in the Treatment of Post-Herpetic Neuralgia
To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.
- Trial name
- NCT00295776
- Testing
- Lamictal in the treatment of Post-Herpetic Neuralgia
- Where
- United States
- Sponsor
- George Washington University
Stevens-Johnson Syndrome, Lyell Syndrome
Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Intro: Dermatology department of Henri Mondor Hospital (Creteil, France), is a reference center for toxic bullous diseases and severe cutaneous drug reactions (Stevens-Johnson syndrome (SJS), Lyell syndrome (toxic epidermal…
- Conditions
- Stevens-Johnson Syndrome, Lyell Syndrome, Drug Reactions, AGEP
- Trial name
- NCT03659227
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Penetrating Keratoplasty, Multiple Graft Failure
Subconjunctival Humira for Boston Keratoprosthesis
This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.
- Conditions
- Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
- Trial name
- NCT06926478
- Testing
- Adalimumab Injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Toxic Epidermal Necrolysis
Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study
The purpose of this study is to determine whether isotretinoin is helpful in treating patients with an adverse cutaneous drug eruption known as toxic epidermal necrolysis (TEN).
- Trial name
- NCT02795143
- Testing
- Isotretinoin
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
The investigators' aim is to study the effects of mechanical expression of meibomian glands on eyelid disease, ocular surface health in the subacute phase of SJS/TEN.
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis
- Trial name
- NCT05145959
- Testing
- Maskin Probe
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Rare Diseases, Toxic Epidermal Necrolyses
Severe Bullous Drug Eruption and Filgrastim
Toxic epidermal necrolysis (TEN) including Stevens Johnson (SJS) and Lyell syndromes represent the most severe drug eruptions. It is an allergic disorder caused by cytotoxic T lymphocytes, specific of drugs, responsible for the…
- Trial name
- GNET (NCT04651439)
- Testing
- Filgrastim
- Where
- 3 sites in France
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Chemical Injuries, Unspecified Complication of Corneal Transplant
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
The purpose of the pilot study is to test the efficacy and safety of riboflavin/Ultraviolet A (UVA) cross-linked human donor corneas as carriers for the Boston Keratoprosthesis (Boston KPro) in patients with higher risk for…
- Conditions
- Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid
- Trial name
- NCT01582880
- Testing
- Riboflavin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph B. Ciolino, MD
SARS-CoV-2 Infection, COVID-19
Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)
Clinical trials of prevention modalities for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and coronavirus disease (COVID-19) and pneumonia are underway under separate protocol(s) for close contacts…
- Conditions
- SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
- Trial name
- IICov19PRS (NCT05074719)
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- University of Washington
Epidermal Necrolysis, Lyell Syndrome
LYell SYndrome MEsenchymal Stromal Cells Treatment
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs.
- Conditions
- Epidermal Necrolysis, Lyell Syndrome, Toxic Epidermal Necrolysis, Overlap Syndrome
- Trial name
- LYSYME (NCT04711200)
- Testing
- Adipose derived stromal cells intravenously injected
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myocardial Infarction, Drug-Coated Balloon
Prevail Drug Balloon Study
This is an investigator-initiated, prospective, single-centre, non-randomized, all-comers registry that evaluates the safety and efficacy of any Paclitaxel Drug-Coated Balloon (DCB) for the treatment of coronary de novo lesion…
- Trial name
- NCT05562089
- Testing
- A Paclitaxel Drug-Coated Balloon
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- Chinese University of Hong Kong
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease
Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease
The PATHFINDER Registry is a prospective, non-randomized, single arm, multicenter observational study. This pilot registry is aimed to evaluate the performance (peri-procedural) and clinical outcomes (intermediate and long-term)…
- Conditions
- Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
- Trial name
- PATHFINDER (NCT04229563)
- Testing
- AURYON Atherectomy System
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- Angiodynamics, Inc.
Peripheral Angioplasty
Computer Prediction of Restenosis Following Peripheral Angioplasty
The purpose of this study is to develop a computer program that might be able to accurately assess the risk of artery re-narrowing following angioplasty or stenting based on computer images.
- Trial name
- NCT01202344
- Testing
- Additional x-ray images
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Dheeraj Rajan
Cutaneous Manifestations, Skin Manifestations
Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019.
- Conditions
- Cutaneous Manifestations, Skin Manifestations, COVID-19, COVID-19 Pneumonia
- Trial name
- NCT05094687
- Where
- Pakistan
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre